United States-based medical device and healthcare company Abbott Laboratories(NYSE: ABT) announced on Saturday its late-breaking outcome from the AVEIR dual-chamber (DR) i2i Investigational Device Exemption (IDE) study, a large-scale study to evaluate the world's first dual-chamber leadless pacemaker.
The study indicated that the leadless pacemaker met its three prespecified primary endpoints for safety and performance. The data further suggests that AVEIR DR could offer new benefits for people with slower-than-normal heart rhythms.
The outcome was revealed during a late-breaking clinical trial session at the Heart Rhythm Society's (HRS) 44th annual meeting in New Orleans and simultaneously published in The New England Journal of Medicine. The company has submitted this data to the US Food and Drug Administration (FDA) as part of its submission for approval of the AVEIR DR device.
Abbott designed the AVEIR DR leadless pacemaker – the DR denoting dual-chamber rate response – with a first-of-its-kind i2i (implant-to-implant) technology, with the goal of providing beat-to-beat communication and synchrony between two leadless pacemakers, a necessary foundation of dual-chamber leadless pacing therapy. Unlike other leadless pacemakers, this system allows the two devices to communicate with each other -- sensing for delayed or missed heartbeat and then pacing the appropriate chamber of the heart.
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial